Skip to main content
OpenTrials
Completed

NCT Number: NCT05680311

Autotaxin: a Potential Biomarker for Breast Cancer.

The goal of this clinical trial is to test the efficiency of Autotaxin (ATX) as a biomarker for breast cancer patients.

The main questions it aims to answer are;

* is ATX a reliable tumor marker for breast cancer patients in diagnosis * can ATX differentiate cancer patients from non-cancer ones

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–80 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Ankara Etlik City Hospital

Ankara, 06170, Turkey (Türkiye)

About this study

80 breast cancer patients and 30 normal patients with no known cancer history were enrolled in this study. All patients were female. The mean ages of cancer patients were 58.2 and 52.7 consecutively for cancer and non-cancer patients. The mean serum ATX levels of cancer and non-cancer patients were 1570.72 and 121.86 ng/mL consecutively (p=0.001). The cut-off value of ATX serum level was 178.49ng/mL according to the ROC analysis. The area under the ROC curve was 0.901showing that ATX is very efficient in distinguishing between two diagnostic groups (diseased/normal). ATX also showed good correlations with known tumor markers (CEA, CA15-3, CA125 levels). ATX levels were still higher than the cut-off value even in cancer patients with normal or low classical tumor marker levels.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Preoperatively diagnosed breast cancer patients with no synchronous cancer and without known hepatic or other inflammatory disorders.

Exclusion criteria

  • Patients with benign breast diseases and no known cancer history.

Treatment and study plan

measurement of serum autotaxin serum level

Biological

autotaxin expression

Primary outcomes

  1. Autotaxin as a tumor marker

    Time frame: preoperative period

    Diagnostic value of Autotaxin in breast cancer

Sponsors and collaborators

Lead sponsor

Ankara Etlik City Hospital

Other Gov

Collaborators

  • Diskapi Yildirim Beyazit Education and Research Hospital

Registry information

Official study title

Is Autotaxin a Promising Biomarker for Breast Cancer

Important dates

Study start
2019
Primary completion
2020
Study completion
2021
First posted
Jan 11, 2023
Registry last updated
Jan 26, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.